Naviter Wealth LLC Has $8.88 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Naviter Wealth LLC grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 7.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 10,801 shares of the company's stock after purchasing an additional 782 shares during the quarter. Eli Lilly and Company comprises approximately 1.1% of Naviter Wealth LLC's holdings, making the stock its 16th largest holding. Naviter Wealth LLC's holdings in Eli Lilly and Company were worth $8,884,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth $43,000. Prudent Man Investment Management Inc. bought a new position in Eli Lilly and Company during the fourth quarter worth about $48,000. Highline Wealth Partners LLC grew its stake in Eli Lilly and Company by 53.3% in the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock valued at $57,000 after acquiring an additional 24 shares during the period. Finally, Capital A Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $63,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on LLY shares. Erste Group Bank cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target on the stock. UBS Group lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.61.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $779.35 on Tuesday. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The company has a market cap of $738.62 billion, a P/E ratio of 63.41, a P/E/G ratio of 1.13 and a beta of 0.41. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The stock's 50-day simple moving average is $779.41 and its 200 day simple moving average is $800.01.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period last year, the firm earned $2.58 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.77%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.